Trials / Completed
CompletedNCT07033533
Allopurinol and Pathogenesis of Cirrhosis
Allopurinol Interferes With the Pathological Mechanisms of Hepatic Decompensation
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Hepatic decompensation is a common healthcare issue . This study was conducted to investigate how allopurinol can interfere with the pathological mechanisms of HD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allopurinol Tablet | allopurinol 300 |
| DRUG | Placebo | placebo tablet |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2024-03-01
- Completion
- 2024-03-01
- First posted
- 2025-06-24
- Last updated
- 2025-06-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07033533. Inclusion in this directory is not an endorsement.